Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOLANO phase 2b study of AZD8233 in hyperlipidaemia
NL-OMON52196Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Aug 2021
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hyperlipidemia and hypercholesterolemia comparing AZD8233 with Placebo (2 arms). Primary endpoints: Safety and tolerability and Relative change in serum LDL-C. Started Aug 2021; status: active, not recruiting.
02
Drugs
AZD8233
03
Conditions
hyperlipidemiahypercholesterolemia
Beyond the preview
Go deeper on NL-OMON52196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52196.